Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca (Cyto-Cog)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00756132|
Recruitment Status : Active, not recruiting
First Posted : September 19, 2008
Last Update Posted : November 1, 2016
|Condition or disease|
|Locally Advanced Breast Cancer Breast Cancer|
|Study Type :||Observational|
|Actual Enrollment :||120 participants|
|Observational Model:||Case Control|
|Official Title:||Role of Inflammatory Markers in Predicting Disease Recurrency and Cognitive Performance in Women With High Risk and Locally Advanced Breast Cancer|
|Study Start Date :||August 2008|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||September 2017|
Bloods Only (B)
Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
- Cognitive performance expressed by raw scores, T and Z scores [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00756132
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||Lori Bernstein, PhD||University Health Network, Princess Margaret Hospital|
|Principal Investigator:||Bostjan Seruga, MD||PMH UHN|